Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Psoriatic arthritis is a condition in which the immune system attacks the joints and causes inflammation. The following symptoms may occur in the fingers, toes, knees, or other areas.

The exact cause of psoriatic arthritis isn't known, but the immune system plays a major role in its development. In general, ...

Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...

Until recently, little was known about psoriatic arthritis (PsA), a disease first described and classified by the medical community in the 1970s. A 2008 Belgian study offered hope to people with ...

While IL-17 blocking agents are linked to an increased risk for candidiasis, bimekizumab, which blocks two proteins ...

For example, psoriasis and psoriatic arthritis can accelerate hardening of the arteries and put people at much higher risk for heart attack and stroke. By managing both inflammatory conditions ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.